+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil



Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil



Tumori 74(3): 329-331



A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented. This syndrome has been described in the literature after protracted infusion chemotherapy of over 30 days. The agent most frequently associated with this syndrome was 5-FU. A 53-year-old man was admitted to the hospital with a well-differentiated squamous cell carcinoma of the retromolar trigone. The patient received 100 mg/m2 of cisplatin on day 1 and 120-h continuous infusion of 1000 mg/m2 of 5-FU every 3 weeks. After the second course, the patient developed clinical features consistent with PPES. This side effect has not been previously reported with short-term (5-day or 120-h) continuous infusion of 5-FU. Less frequently, the syndrome has also been described with 10-day continuous infusion. The etiopathogenesis of PPES is unclear, but it seems to be dose-dependent and probably related to cutaneous drug accumulation.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040903913

Download citation: RISBibTeXText

PMID: 3400123


Related references

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Investigational New Drugs 8(1): 57-63, 1990

Fluorouracil and the palmar-plantar erythrodysesthesia syndrome. Annals of Internal Medicine 102(3): 419, 1985

Fluorouracil and palmar-plantar erythrodysesthesia. Annals of Internal Medicine 111(10): 858, 1989

Pharmacokinetic properties of high dose leucovorin in combination with conventional dose 5 fluorouracil administered by short term infusion or by 5 days continuous infusion. Journal of Clinical Pharmacology 26(7): 556, 1986

Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Annals of Internal Medicine 111(8): 688-689, 1989

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Annals of Internal Medicine 101(6): 798-799, 1984

Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 20(10): 1221-1223, 2000

Hand-foot syndrome (palmar-plantar erythrodysesthesia. Schweizerische Medizinische Wochenschrift 130(40): 1413-1416, 2000

Antineoplastic TherapyInduced Palmar Plantar Erythrodysesthesia (Hand-Foot) Syndrome. American Journal of Clinical Dermatology 1(4): 225-234, 2000

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Supportive Cancer Therapy 1(4): 213-218, 2008

Cutaneous toxicity by ftorafur, hand-foot or palmar-plantar erythrodysesthesia syndrome. Revista Clinica Espanola 188(3): 165-166, 1991

Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?. Annals of Oncology 16(7): 1210-1211, 2005

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Annals of Oncology 18(7): 1159-1164, 2007

Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. Journal of the Royal Society of Medicine 88(6): 356p-357p, 1995

Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. European Journal Of Cancer. 33(6): 967-969, 1997